Pin Therapeutics at TPD Summit 2026

Oct 26–29, 2026 Boston, MA ~300 attendees Website

Pin Therapeutics takes part in 2 sessions at TPD Summit 2026 in Boston. Its sessions cover a degrader platform built on a new E3 ligase meant to avoid blood-related toxicity, and how early clinical signals can guide efficacy and safety strategy.

OrganizationTPD Summit 2026 Attendance
pintherapeutics.com
Biotech
Develops targeted protein degraders that use a new E3 ligase, aiming to reduce hematologic toxicity.
Talk
Tue Oct 27
12:30pm
A Novel TPD Platform Leveraging a New E3 Ligase to Minimize Hematologic Toxicity
Track A: Discovery
Panel
Wed Oct 28
2:00pm
Translating Early Clinical Signals into Strategies for Maximizing Efficacy & Safety of Induced Proximity Therapeutics
Track C: Translational & Clinical Development · with PAQ Therapeutics, Takeda

Explore the full TPD Summit 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full TPD Summit 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Pin Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction